drugset
drugset / Trial / NCT00086216

Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

NCT00086216 ↗

Phase 1/2 Completed 30 enrolled Callisto Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.

Timeline

Start
2004-05
Primary completion
—
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atiprimod Small molecule 30 mg Oral
Subject Atiprimod Small molecule 60 mg Oral
Subject Atiprimod Small molecule 90 mg Oral
Subject Atiprimod Small molecule 120 mg Oral
Subject Atiprimod Small molecule 180 mg Oral
Subject Atiprimod Small molecule 240 mg Oral
Subject Atiprimod Small molecule 300 mg Oral
Subject Atiprimod Small molecule 360 mg Oral
Subject Atiprimod Small molecule 420 mg Oral
Subject Atiprimod Small molecule 480 mg Oral

Indications

plasma cell myeloma